Search Results

Featured Stories

Toggle

Showing 10 of 368 results

Teva Reports First Quarter 2021 Financial Results

Revenues of $4.0 billion GAAP diluted EPS of $0.07 Non-GAAP diluted EPS of $0.63 Cash flow used in operating activities of $405 million Free cash flow of $59 million Full year 2021 business outlook...

Teva to Present at the J.P. Morgan 2021 Global High Yield and Leveraged Finance Conference

TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Executive Vice President & CFO Eli Kalif will present at the J.P. Morgan 2021 Glob...

Teva Reports Fourth Quarter and Full Year 2020 Financial Results

  TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2020. This press release...

Teva Reports Third Quarter 2020 Financial Results

Revenues of $4.0 billion GAAP diluted loss per share of $3.97 Non-GAAP diluted EPS of $0.58 Free cash flow of $506 million Full year 2020 business outlook revised: Net revenues of $16.5-16.8 billio...

Teva Reports Fourth Quarter and Full Year 2019 Financial Results

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2019. Full-Year 2019 and Q4 2019 Highlights :       FY 2019   Q4 201...

Teva Announces Early Tender Results of its Debt Tender Offer and Election of Early Settlement

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today the early tender results in connection with its previously announced tender offers (the “ Offers ”) to purchase...

Teva Announces Successful Upsize of Senior Notes Offering and Pricing of $2.1 Billion of Senior Notes

Proceeds to Repay Existing Debt Teva Pharmaceutical Industries Limited (NYSE and TASE: TEVA) (“ Teva ”) announced today that it successfully upsized and priced approximately $2.1 billion (equivalen...

Teva Announces $1.5 Billion Debt Tender Offers

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it has commenced tender offers (the “ Offers ”) to purchase for cash for a combined aggregate purchase price (exclusiv...

Teva Announces Launch of $1,500,000,000 Offering of Senior Notes

Teva Pharmaceutical Industries Limited (NYSE and TASE: TEVA) (“ Teva ”) announced today the following private offering of senior notes: Teva Pharmaceutical Finance Netherlands II B.V. (“ Teva Finan...

Teva Announces Appointment of New Chief Financial Officer

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today the appointment of Eli Kalif as Executive Vice President and Chief Financial Officer. Mr. Kalif will begin his employment o...